HTA26 Duration and Timing of Treatment Waning: Determining the Start and Stop Points Using Pembrolizumab in NSCLC As a Case Study
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.1455
https://www.valueinhealthjournal.com/article/S1098-3015(23)01555-3/fulltext
Title :
HTA26 Duration and Timing of Treatment Waning: Determining the Start and Stop Points Using Pembrolizumab in NSCLC As a Case Study
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)01555-3&doi=10.1016/j.jval.2023.03.1455
First page :
Section Title :
Open access? :
No
Section Order :
10861